Clinical Trials Arena March 4, 2025
With the first therapies approved for solid tumors and new breakthroughs in diabetes treatments, the last year been notable in advancing cell and gene therapies.
The previous 12 months have seen considerable progress in cell and gene therapies, with the first solid tumor products receiving regulatory approval and applicants for treating diabetes and heart disease.
As CGT scale-up continued through the year, overcoming logistical hurdles, artificial intelligence (AI) helped optimize processes to ensure more patients could benefit from life-saving treatments.
These developments strongly indicate that the future is bright for the CGT market, which GlobalData forecasts will be worth $80 billion by 2030 — up from $6 billion in 2023.1 With so many breakthroughs in one year, the industry is...
Today's Sponsors
Today's Sponsor